Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Net Income (2023 - 2025)

Immunocore Holdings' Net Income history spans 3 years, with the latest figure at -$30.0 million for Q4 2025.

  • For Q4 2025, Net Income fell 26.55% year-over-year to -$30.0 million; the TTM value through Dec 2025 reached -$35.5 million, up 30.48%, while the annual FY2025 figure was -$35.5 million, 30.48% up from the prior year.
  • Net Income for Q4 2025 was -$30.0 million at Immunocore Holdings, down from -$177000.0 in the prior quarter.
  • Across five years, Net Income topped out at $8.7 million in Q3 2024 and bottomed at -$30.0 million in Q4 2025.
  • The 3-year median for Net Income is -$14.3 million (2023), against an average of -$11.8 million.
  • The largest annual shift saw Net Income soared 858.43% in 2024 before it crashed 102.04% in 2025.
  • A 3-year view of Net Income shows it stood at -$19.7 million in 2023, then fell by 20.26% to -$23.7 million in 2024, then decreased by 26.55% to -$30.0 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Net Income are -$30.0 million (Q4 2025), -$177000.0 (Q3 2025), and -$10.3 million (Q2 2025).